IMW 2026: vídeos e entrevistas
172 vídeos do IMW 2026 publicados por Targeted Oncology, VJHemOnc. Atualizado em 20/11/2026.
How may exercise and orthopedic care support bone health in patients with myeloma from diagnosis?VJHemOnc · 10/11/2026 · 2:37 · apoio da indústria
How may serial sampling of cfDNA track disease dynamics and detect early progression in myeloma?VJHemOnc · 10/11/2026 · 1:37 · apoio da indústria
Prognostic value of using NGF to identify aberrant plasma cell subtypes in newly diagnosed myelomaVJHemOnc · 10/11/2026 · 1:46 · apoio da indústria
Update from DART4MM: daratumumab consolidation after ASCT in patients with multiple myelomaVJHemOnc · 10/11/2026 · 2:30 · apoio da indústria
Identifying racial and socioeconomic disparities in second primary malignancy onset in myelomaVJHemOnc · 10/11/2026 · 1:37 · apoio da indústria
Insights into a SEER analysis of non-cancer mortality trends in multiple myelomaVJHemOnc · 10/11/2026 · 1:42 · apoio da indústria
Choosing between imaging modalities in multiple myeloma: advice for physiciansVJHemOnc · 10/11/2026 · 1:57 · apoio da indústria
Insights into premedication and infusion-related reactions with subcutaneous isatuximab in myelomaVJHemOnc · 10/11/2026 · 1:40 · apoio da indústria
AI-designed BCMA/FcRL5 targeting trispecific antibody to overcome antigen escape in multiple myelomaVJHemOnc · 06/11/2026 · 2:40 · apoio da indústria
Outpatient ramantamig administration in myeloma: managing CRS and neurotoxicityVJHemOnc · 03/11/2026 · 2:19 · apoio da indústria
Managing dose interruptions and re-treatment with T-cell engagers in myelomaVJHemOnc · 03/11/2026 · 1:18 · apoio da indústria
Ramantamig and dual-antigen targeting in relapsed/refractory myelomaVJHemOnc · 03/11/2026 · 1:20 · apoio da indústria
Discussing the concept of a cure in multiple myeloma: is the term over-promising?VJHemOnc · 03/11/2026 · 3:01 · apoio da indústria
Whole-body MRI and progression risk in smoldering myelomaVJHemOnc · 03/11/2026 · 2:10 · apoio da indústria
Peripheral neuropathy in smoldering myelomaVJHemOnc · 03/11/2026 · 2:04 · apoio da indústria
Macrophage reprogramming and response to PD-1 blockade in smoldering myelomaVJHemOnc · 03/11/2026 · 1:25 · apoio da indústria
CAR T-cell therapy versus bispecific antibodies in high-risk smoldering myelomaVJHemOnc · 03/11/2026 · 1:10 · apoio da indústria
Managing CNS-involved myeloma: CAR T-cell access and alternative treatment strategiesVJHemOnc · 03/11/2026 · 1:11 · apoio da indústria
Anti-BCMA CAR T-cell therapy in CNS-involved myeloma: safety and long-term outcomesVJHemOnc · 03/11/2026 · 3:49 · apoio da indústria
DREAMM-9: extended belantamab dosing and vision-related outcomes in myelomaVJHemOnc · 03/11/2026 · 6:09 · apoio da indústria
Genomic risk stratification and treatment consistency in myelomaVJHemOnc · 03/11/2026 · 1:24 · apoio da indústria
The role of CELMoDs in relapsed myelomaVJHemOnc · 03/11/2026 · 1:17 · apoio da indústria
Implementing MRD-guided treatment in community myeloma careVJHemOnc · 03/11/2026 · 2:18 · apoio da indústria
GEM-TECTAL: MRD-guided T-cell redirection in high-risk myelomaVJHemOnc · 03/11/2026 · 2:29 · apoio da indústria
LENAZART: lenalidomide, oral azacitidine, & radiotherapy in newly diagnosed & relapsed plasmacytomaVJHemOnc · 03/11/2026 · 3:31 · apoio da indústria
The association between high blood sugar and CAR-T outcomes in multiple myelomaVJHemOnc · 03/11/2026 · 5:58 · apoio da indústria
Real-world outcomes of DVd in myeloma at first relapse and its role in the evolving landscapeVJHemOnc · 03/11/2026 · 1:21 · apoio da indústria
MRD-guided maintenance discontinuation in myeloma: long-term results from GEM2014MAINVJHemOnc · 02/11/2026 · 2:51 · apoio da indústria
Infection-related mortality in myeloma: trends, disparities and prevention strategiesVJHemOnc · 02/11/2026 · 1:59 · apoio da indústria
Self-administration of bortezomib in myeloma and amyloidosis: feasibility study findingsVJHemOnc · 02/11/2026 · 3:29 · apoio da indústria
Phase II MODIFY trial: isatuximab, iberdomide, and dexamethasone in high-risk smoldering myelomaVJHemOnc · 02/11/2026 · 3:16 · apoio da indústria
Cilta-cel in earlier-line myeloma: insights into updated survival dataVJHemOnc · 29/10/2026 · 1:17 · apoio da indústria
ASCO Living Guideline updates in multiple myeloma: CAR T-cell therapy versus bispecific antibodiesVJHemOnc · 29/10/2026 · 3:15 · apoio da indústria
CAR T-cell therapy in R/R myeloma: adverse-event management costs and treatment selectionVJHemOnc · 29/10/2026 · 2:44 · apoio da indústria
Identifying patients who need curative treatment versus disease control in myelomaVJHemOnc · 29/10/2026 · 3:46 · apoio da indústria
The future of AI in hematology: personalized medicine, opportunities and risksVJHemOnc · 29/10/2026 · 2:30 · apoio da indústria
The ethical challenges of AI in hematology: patient communication, trust and regulationVJHemOnc · 29/10/2026 · 3:12 · apoio da indústria
Advances in myeloma treatment: quadruplets, CAR T-cell therapy and bispecific antibodiesVJHemOnc · 29/10/2026 · 4:55 · apoio da indústria
The role of patient preference in selecting treatment administration routes in multiple myelomaVJHemOnc · 29/10/2026 · 1:35 · apoio da indústria
Patient satisfaction with subcutaneous isatuximab in myeloma: IRAKLIA and IZALCOVJHemOnc · 29/10/2026 · 2:02 · apoio da indústria
On-body injector delivery of subcutaneous isatuximab in multiple myelomaVJHemOnc · 27/10/2026 · 1:38 · apoio da indústria
Ex vivo drug sensitivity profiling to guide treatment selection in R/R multiple myelomaVJHemOnc · 27/10/2026 · 1:47 · apoio da indústria
Addressing access challenges to bispecifics for patients with multiple myeloma in Asian countriesVJHemOnc · 21/10/2026 · 2:06 · apoio da indústria
Multi-omics reveals a molecular signature in TP53-mutated myeloma: insights & clinical implicationsVJHemOnc · 21/10/2026 · 2:42 · apoio da indústria
Key updates on newly diagnosed multiple myeloma: progress and challenges in high-risk diseaseVJHemOnc · 21/10/2026 · 2:34 · apoio da indústria
Exploring arginine metabolism and ASS1 status in t(11;14) myelomaVJHemOnc · 21/10/2026 · 4:24 · apoio da indústria
Pre-treatment genomic screening to guide venetoclax-based sequencing in t(11;14) myelomaVJHemOnc · 21/10/2026 · 1:09 · apoio da indústria
The potential benefits of fixed-duration bispecific antibody therapy in multiple myelomaVJHemOnc · 16/10/2026 · 1:22 · apoio da indústria
CAMMA 1: fixed-duration cevostamab shows durable responses in R/R multiple myelomaVJHemOnc · 16/10/2026 · 6:22 · apoio da indústria
Individualized bridging therapy before BCMA-directed CAR T-cell therapyVJHemOnc · 15/10/2026 · 1:17 · apoio da indústria
Hypogammaglobulinemia, infection risk, and IgG replacement therapy in myelomaVJHemOnc · 15/10/2026 · 1:46 · apoio da indústria
Efficacy and safety of GPRC5D-targeted QLS32015 in multiple myelomaVJHemOnc · 14/10/2026 · 2:49 · apoio da indústria
Outpatient administration of T-cell-redirecting antibodies in multiple myelomaVJHemOnc · 14/10/2026 · 1:28 · apoio da indústria
TRIlogy-1 trial: updated ramantamig safety and efficacy data in relapsed/refractory multiple myelomaVJHemOnc · 14/10/2026 · 1:35 · apoio da indústria
CERVINO trial results and the potential role of etentamig in multiple myelomaVJHemOnc · 14/10/2026 · 1:19 · apoio da indústria
IMS 2026 highlights: evolving multiple myeloma treatment and the path toward cureVJHemOnc · 14/10/2026 · 7:00 · apoio da indústria
Implementing bispecific antibodies in triple-class-exposed multiple myelomaVJHemOnc · 14/10/2026 · 1:46 · apoio da indústria
Long-term outcomes with KRd versus Rd in high-risk smoldering multiple myelomaVJHemOnc · 14/10/2026 · 4:22 · apoio da indústria
Supplement use in MGUS, smoldering myeloma, and multiple myeloma: findings from a patient surveyVJHemOnc · 14/10/2026 · 3:12 · apoio da indústria
NUTRIVENTION-5: a decentralized trial of a plant-based diet during induction therapy in NDMMVJHemOnc · 14/10/2026 · 4:50 · apoio da indústria